- CNBC•51 minutes ago
See which stocks are posting big moves after the bell.
- Investor's Business Daily•58 minutes ago
Amgen stock toppled in after-hours trading Wednesday after reporting first-quarter sales that missed by $100 million on increased competition for several drugs.
- Reuters•1 hour ago
Sales of Enbrel, faced with increased competition and slowing growth in the rheumatology and dermatology sectors, dropped 15 percent to $1.18 billion, below Wall Street estimates of about $1.38 billion. Enbrel has traditionally been a growth driver for Amgen, although the company had cautioned that pricing pressure would likely hit the franchise this year. It's in decline," said Cowen and Co analyst Eric Schmidt, adding that inventory stocking in the prior quarter likely contributed to the sales drop.
AMGN : Summary for Amgen Inc. - Yahoo Finance
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||159.40 x 300|
|Ask||159.50 x 100|
|Day's Range||164.34 - 165.40|
|52 Week Range||133.64 - 184.21|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||16.08|
|Dividend & Yield||4.60 (2.84%)|
|1y Target Est||N/A|